- Home
- Equipment
- north america
- vascular temporary occlusion
Show results for
Refine by
Vascular Temporary Occlusion Equipment Supplied In North America
5 equipment items found
Manufactured by:Raumedic AG based inDietzenbach, GERMANY
Safety and flexibility in angiography thanks to high-pressure tubing. In angiography, blood vessels are made visible by means of X-rays (CT) or magnetic resonance (MRI). To identify even the smallest ramifications of the blood vessels, a contrast agent is required which is injected into the body with high pressure via the tubes. During the application, the high-pressure tubing must withstand the ...
Manufactured by:Baylis Medical Technologies based inMississauga, ONTARIO (CANADA)
The PowerWire Pro RF Guidewire is developed for effective management of complex vascular occlusions, utilizing radiofrequency puncture technology to create channels through peripheral vessels both native and stented. In the USA, it's indicated for use in totally occluded peripheral vessels of 3 mm or greater while in Canada, it is used for treating occlusive peripheral vascular diseases to aid ...
Manufactured by:Okami Medical based inAliso Viejo,, CALIFORNIA (USA)
The LOBO occluder is the first and only peripheral embolization device featuring proprietary HDBRAID™ technology – an innovative, unique braiding method developed specifically for making devices to occlude vessels. With this method, braided devices can be made with wires less than 20 microns in diameter – about ¼ the thickness of a human hair. Most vascular occluders rely ...
Manufactured by:Carbon Medical Technologies, Inc. based inSt. Paul, MINNESOTA (USA)
Durasphere is an injectable bulking agent containing pyrolytic carbon-coated graphite beads suspended in a water-based carrier gel containing beta glucan. It is used in the treatment of stress urinary incontinence. Durasphere is a highly biocompatible, permanent material that can be administered in less than 30 minutes in a simple office-based ...
Manufactured by:United Therapeutics Corporation based inSilver Spring, MARYLAND (USA)
Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases ...